Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany.

Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Meinerz, Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Meinerz, W., 2015.

Annual Meeting ESGO (Society of Gynaecological Oncology) (0919).